ClinicalTrials.gg
TerminatedNCT06161792VMSUpdated Dec 8, 2023

Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer

A Phase 2 interventional study of 0.8 mg RCN3028 and Placebo in Hot Flashes and Breast Cancer, sponsored by Yung Shin Pharm. Ind. Co., Ltd.. Terminated at 4 sites in Taiwan. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-08.

Sponsored by Yung Shin Pharm. Ind. Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Difficulty in recruiting breast cancer patients, leading to a slow rate of case enrollment.

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Nov 2019, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Study summary

Due to the fact that majority of breast cancers are estrogen-receptor and/or progesterone receptor positive, tamoxifen and aromatase inhibitors (AIs) are among the mainstay therapies to treat breast cancer. Prior clinical studies of tamoxifen suggested that up to 80 % of patients experienced hot flashes during therapy with tamoxifen, and 30 % defined their symptoms as severe. Despite the high efficacy of tamoxifen, the harmful side effects have been identified in previous studies as a significant reason for not persisting with the treatment in 16 - 30 % of breast cancer patients.

The primary purpose of this study is to determine if RCN3028 is effective and safe in the treatment of moderate to severe vasomotor symptoms associated. In accordance with the latest FDA guidance study participants will have a minimum of 7 moderate to sever hot flashes per day, or 50 per week at baseline.

Read the detailed description

Hot flashes are the most common symptom of menopause and affect almost 75% of menopausal women. Clinical evidence indicates potent antagonists of 5-HT2a are more likely to cause hypothermia. Risperidone is a potent 5-HT2a and a dopamine D2 receptor antagonist and is proposed to have effect on reduction of hot flashes through its dopaminergic and serotonergic antagonism.

Breast cancer is one of the most common cancers in women, according to the cancer registration report of the Ministry of Health and Welfare (MOHW), in 2014, up to 11,976 women suffered from breast cancer, which meant 33 women suffered from breast cancer daily. Recent epidemiology further disclosed that the incidence of breast cancer was top-ranked (70.74 per 100,000) among cancers of Taiwanese women in 2014.

Due to the fact that majority of breast cancers are estrogen-receptor and/or progesterone receptor positive, tamoxifen and aromatase inhibitors (AIs) are among the mainstay therapies to treat breast cancer. Prior clinical studies of tamoxifen suggested that up to 80 % of patients experienced hot flashes during therapy with tamoxifen, and 30 % defined their symptoms as severe. Despite the high efficacy of tamoxifen, the harmful side effects have been identified in previous studies as a significant reason for not persisting with the treatment in 16 - 30 % of breast cancer patients.

The primary purpose of this study is to determine if RCN3028 is effective and safe in the treatment of moderate to severe vasomotor symptoms associated. In accordance with the latest FDA guidance study participants will have a minimum of 7 moderate to sever hot flashes per day, or 50 per week at baseline.

With recent advances of treatment modalities, more than 80% of women with a newly diagnosed breast cancer are expected to survive their disease for 5 years or more. One of the most common complaints was hot flashes induced by the treatment of breast cancer (i.e., tamoxifen induced hot flashes).

In general, hormone replacement therapy (HRT) is the most effective treatment for VMS (hot flashes). However, HRT has been associated with increased risk of recurrence in breast cancer survivors . Moreover, there is some evidence that HRT may not be as effective in women using tamoxifen. Therefore, a new therapy for treating hot flashes in breast cancer patients without increasing the risk of cancer recurrence is needed for such patient population, for example, a non-hormonal therapy. FDA approved low-dose paroxetine capsules (Brisdelle®) as a non-hormonal therapy for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, despite the modest efficacy as compared with placebo, suicidal ideation and the drug-drug interactions (i.e., Brisdelle® and tamoxifen) . Brisdelle® itself is an antidepressant of selective serotonin reuptake inhibitors (SSRI) class. Several trials have recently demonstrated a role for SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the treatment of VMS.

02

Conditions studied

  • Hot Flashes
  • Breast Cancer

Keywords

  • Hot Flashes
03

In context

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

This study's enrollment of 10 is below the median of 90 across 306 interventional studies indexed under Hot Flashes.

Browse Hot Flashes studies →

Lead sponsor

Yung Shin Pharm. Ind. Co., Ltd. is the lead sponsor of 19 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects (aged 20 years or order) with confirmed diagnosis of breast cancer who have completed chemotherapy and radiotherapy, and are on a stable dose of tamoxifen or aromatase inhibitors (AIs) for at least 8 weeks at baseline and will maintain the same treatment regimen and dose throughout the study.
  • Reported 7 or more moderate to severe hot flashes per day (average) or 50 moderate to severe hot flashes per week at baseline.
  • Screening laboratory values for hematopoietic, hepatic, and renal functions are within the following ranges:

    • Hematopoietic : ≥ 1,500/mm3、 count ≥ 100,000/mm3
    • Hepatic : Glutamic Oxaloacetic Transaminase/Glutamic Pyruvic Transaminase ≤ 3 times (ULN)、 ≤ 1.5 times ULN
    • Renal : Creatinine ≤ 1.5 times ULN
  • Having Eastern Collaborative Oncology Group () Performance Status of ≤ 1.
  • Ability to understand and follow the instructions of the investigator, including completion of the study procedures as described in the protocol (i.e., VMS episode event log).
  • Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • Subjects are pregnant or breastfeeding.
  • Female subjects who have , but they are not willing to use effective methods during study period and for 1 week afterward.
  • Subjects who have multiple primary cancers (except for completely resected basal cell cancer, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer or any other cancer from which the patient has been recurrence-free for at least 5 years).
  • Subjects who have inoperable breast cancer (Stage IIIB/IIIC/IV).
  • Subjects who have the following medical history: myocardial infarction, congestive heart failure, significant ischemic or valvular heart disease, clinically active interstitial lung disease.
  • Subjects who have systolic blood pressure (BP) outside the range 100 to 150 mmHg, diastolic BP outside the range 60 to 90 mmHg, and/or heart rate outside the range 50 to 100 bpm at baseline.
  • Subjects who had received treatment for hypotension within 30 days prior to screening visit.
  • Subjects who have uncontrolled hyperglycemia, ≥ 7% at baseline.
  • Subjects who have clinical significant conditions such as acute myocardial infarction or stroke with 6 months of randomization.
  • Subjects who have a history of Parkinson's disease.
  • Subjects are taking risperidone in the 30 days prior to screening visit.
  • Subjects who had participated in another clinical trial and received an drug within 30 days prior to screening visit.
  • Subjects having a known history of allergic reaction, or intolerance to ingredients of the study drug.
  • Subjects with a current drug or alcohol abuse problem as judged by the investigator.
  • Subjects who are considered unreliable as to medication compliance or adherence to scheduled appointments or for other reasons are felt to be inappropriate for inclusion in the study as determined by the investigators.
  • Subjects who use Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), within 4 weeks prior to screening visit.
  • Subjects who use herbal or dietary supplements, including black cohosh, soy, phytoestrogens or over the counter agents known to possibly be effective for the treatment of vasomotor symptoms within 2 weeks prior to baseline.
  • Subjects who have serious, unstable, or clinically significant medical or psychological conditions, which, in the opinion of the investigator(s), would compromise the subject's participation in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Placebo comparator
    I placebo capsule

    Subjects will be enrolled to about 14-days of placebo-run-in period. Other Names: RCN3028 placebo

    Drug: Placebo

  • Experimental
    II RCN3028 0.8 mg capsule

    Subjects will be enrolled to about 14-days of placebo-run-in period. Treatment started at 0.4 mg, titrated to 0.8 mg for maintenance phase. Other Names: RCN3028 0.8 mg capsule

    Drug: 0.8 mg RCN3028

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in frequency of moderate to severe VMS

    Mean change in frequency numbers of moderate to severe VMS(Vasomotor Symptoms) from baseline to weeks 4 and week 12. The VMS episode event log recorded the frequency of hot flashes per day, such mild, moderate, severe, nighttime awakening number.

    Time frame: 4, 12 weeks

  2. Mean change in severity of moderate to severe VMS

    Mean change in severity score of moderate to severe VMS from baseline to weeks 4 and week 12. The severity score for VMS for each subject is calculated as the sum of 2 times the number of moderate VMS, plus 3 times the number of severe VMS, divided by the total number of moderate and severe VMS.

    Time frame: 4, 12 weeks

Secondary outcomes

  1. Menopause Specific Quality of Life Questionnaire

    Menopause Specific Quality of Life Questionnaire will be completed at baseline, week 4, week 8 and week 12. Score on a scale Menopause Specific Quality of Life (MENQOL) questionnaire 0=not bothered at all - 6=extremely bothered. 4 domains, mean calculated for set of questions in each domain.

    Time frame: 12 weeks

  2. The 50%, 75% and 100% responder rates

    Subject who had a reduction in the number of moderate and severe hot flashes of at least 50%, at least 75% and 100% from baseline.

    Time frame: 12 weeks

  3. The time to onset of efficacy

    50% reduction in hot flashes for at least 3 consecutive days. The duration of first treatment used to first onset on efficacy will be calculated.

    Time frame: 12 weeks

  4. Subject's and Physician's Global Assessment

    At the end of treatment Visit (week 12) each subject will provide an overall evaluation of study treatment by completing a Subject's Global Assessment. The rating scale for the final assessment by the subject includes: much worse, worse, unchanged, improved, much improved or free of symptoms. At week 12 each investigator will be asked to rate their subject's response to therapy using the same scale.

    Time frame: 12 weeks

  5. Frequencies(number and percentage) of subjects with treatment-emergent AEs (TEAEs)

    Frequencies (number and percentage) of subjects with one or more treatment-emergent AEs (TEAEs) will be summarized by treatment arm, by the Medical Dictionary for Regulatory Activities (MedDRA) system with respect to System Organ Class (SOC) and preferred term.

    Time frame: 12 weeks

  6. Change from baseline in weekly weighted severity score.

    calculated for each week as 2 times the number of moderate hot flashes plus 3 times the number of severe hot flashes plus 3 times the number of nighttime awakenings. The severity of VMS is defined as follows: 1. Mild: sensation of heat without sweating; 2. Moderate: sensation of heat with sweating, able to continue activity; 3. Severe: sensation of heat with sweating, causing cessation of activity. 4. Nighttime awakenings (i.e., episodes that wake the patient from sleep) associated with hot flashes are recorded separately and are considered severe.

    Time frame: 12 weeks

  7. Change from baseline in the number of mild, moderate, and severe hot flashes.

    The weekly frequency will be calculated for each visit.

    Time frame: 12 weeks

  8. Change from baseline in the number of nighttime awakenings because of hot flashes.

    The weekly frequency will be calculated for each visit.

    Time frame: 12 weeks

07

Study locations

4 sites
  • Changhua Christain Hospital
    Changhua, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • Taipei Medical University Hospital
    Taipei, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Mar 2022, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Dec 8, 2023
StartActual
Nov 7, 2019
Primary completionActual
Mar 14, 2022
CompletionActual
Apr 20, 2022
Last update
Dec 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06161792
Lead sponsor
Yung Shin Pharm. Ind. Co., Ltd.
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Nov 7, 2019
Primary completion
Mar 14, 2022
Completion
Apr 20, 2022
Last update
Dec 8, 2023

Study contacts

hui-Ling Shieh, PhD
study director · Yung Shin Pharm. Ind. Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion